HomeFile

File

Virtual ACC 2020 | Colchicine After Infarction: Good Results and Cost-Effectiveness

Low doses of colchicine reduce the risk of ischemic events after an acute myocardial infarction, according to...

Virtual ACC 2020 | TAILOR-PCI: Gene-Based Prescribing of Clopidogrel Does Not Change Outcomes

This very interesting work leaves us with a sour taste in our mouth, as it failed to...

Virtual ACC 2020 | Vericiguat: New Hope in Chronic Cardiac Failure

Treatment with the new drug called Vericiguat (acting on guanosine monophosphate receptors GMP) might reduce cardiovascular mortality...

Virtual ACC 2020 | VOYAGER PAD: Rivaroxaban Superior to Aspirin in Preventing Events

In patients with peripheral artery disease undergoing revascularization, the combination of rivaroxaban (Xarelto) and low doses of...

Virtual ACC 2020 | More data from ISCHEMIA: Women with More Symptoms but Less Ischemia

The ISCHEMIA trial will keep shedding light. The latest data show important differences between men and women...

Virtual ACC 2020 | COMPASS Sub-Analysis: Diabetes Increases the Benefit of Rivaroxaban Combined with AAS

In patients with stable coronary or peripheral artery disease, diabetes increases the benefit of combining low doses...

16 Years of Superiority of Primary Angioplasty

The DANish Acute Myocardial Infarction 2 (DANAMI-2) trial showed the 30-day superiority of patient transport to a...

Virtual ACC 2020 | More Evidence in Support of the Demanding 2017 Hypertension Guidelines

It’s been a while since the demanding and tough 2017 document written jointly between ACC and AHA...